Trial Profile
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Monalizumab (Primary) ; Monalizumab (Primary) ; Oleclumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACIFIC-9
- Sponsors AstraZeneca; AstraZeneca AB
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 03 May 2023 According to Innate Pharma media release, data from this study will be presented at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting, taking place June 2-6, 2023.
- 09 Aug 2022 Trial design presented at the 2022 World Conference on Lung Cancer.